DekaBank Deutsche Girozentrale Has $8.35 Million Stock Position in Laboratory Co. of America Holdings (NYSE:LH)

DekaBank Deutsche Girozentrale lifted its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 8.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,365 shares of the medical research company’s stock after acquiring an additional 3,107 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Laboratory Co. of America were worth $8,345,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Nordea Investment Management AB boosted its stake in Laboratory Co. of America by 7.5% during the 4th quarter. Nordea Investment Management AB now owns 1,901,111 shares of the medical research company’s stock valued at $386,971,000 after purchasing an additional 132,458 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Laboratory Co. of America by 1.4% in the fourth quarter. Lazard Asset Management LLC now owns 1,426,695 shares of the medical research company’s stock valued at $290,403,000 after purchasing an additional 19,075 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Laboratory Co. of America by 1.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,405,515 shares of the medical research company’s stock valued at $286,074,000 after buying an additional 17,800 shares during the last quarter. Morgan Stanley grew its holdings in Laboratory Co. of America by 56.6% during the fourth quarter. Morgan Stanley now owns 1,214,677 shares of the medical research company’s stock worth $247,247,000 after buying an additional 439,086 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in Laboratory Co. of America by 5.0% in the 4th quarter. UBS Asset Management Americas Inc. now owns 1,083,093 shares of the medical research company’s stock valued at $220,464,000 after buying an additional 51,718 shares during the last quarter. Institutional investors own 89.31% of the company’s stock.

Several analysts have recently commented on LH shares. Wolfe Research downgraded shares of Laboratory Co. of America from an “outperform” rating to a “peer perform” rating in a report on Friday, January 8th. JPMorgan Chase & Co. raised their target price on Laboratory Co. of America from $261.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 12th. Mizuho increased their target price on shares of Laboratory Co. of America from $242.00 to $267.00 and gave the stock a “buy” rating in a research report on Friday, February 12th. Jefferies Financial Group restated a “buy” rating on shares of Laboratory Co. of America in a research note on Thursday, April 1st. Finally, Citigroup increased their target price on Laboratory Co. of America from $257.00 to $278.00 and gave the stock a “buy” rating in a research report on Friday, February 12th. Two investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $237.87.

Shares of LH stock opened at $254.75 on Friday. The company has a market capitalization of $24.87 billion, a PE ratio of 29.66, a price-to-earnings-growth ratio of 1.15 and a beta of 1.09. Laboratory Co. of America Holdings has a 52-week low of $136.38 and a 52-week high of $259.29. The business’s fifty day moving average is $244.20 and its 200 day moving average is $216.69. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.23 and a current ratio of 1.36.

Laboratory Co. of America (NYSE:LH) last announced its earnings results on Wednesday, February 10th. The medical research company reported $10.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.11 by $2.45. The business had revenue of $4.49 billion for the quarter, compared to analyst estimates of $3.98 billion. Laboratory Co. of America had a return on equity of 21.05% and a net margin of 6.79%. On average, sell-side analysts forecast that Laboratory Co. of America Holdings will post 20.84 EPS for the current fiscal year.

In related news, CAO Peter J. Wilkinson sold 2,317 shares of the company’s stock in a transaction on Thursday, February 18th. The shares were sold at an average price of $241.51, for a total value of $559,578.67. Following the completion of the transaction, the chief accounting officer now directly owns 710 shares in the company, valued at $171,472.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mark S. Schroeder sold 667 shares of the stock in a transaction on Tuesday, March 30th. The shares were sold at an average price of $251.88, for a total value of $168,003.96. Following the completion of the transaction, the executive vice president now directly owns 5,006 shares in the company, valued at approximately $1,260,911.28. The disclosure for this sale can be found here. Insiders own 0.70% of the company’s stock.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Recommended Story: Circuit Breakers

Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.